万古霉素和替考拉宁治疗ICU耐甲氧西林金黄色葡萄球菌感染的评价  

EVALUATION OF VANCOMYCIN AND TEICOPLANIN IN THE TREATMENT OF INFECTION CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN INTENSIVE CARE UNIT

作　　者：孙晓霞[1] 方巍[1] 孙运波[1] 

机构地区：[1]青岛大学医学院附属医院ICU,山东青岛266003

出　　处：《齐鲁医学杂志》2009年第6期533-534,537,共3页Medical Journal of Qilu

摘　　要：目的比较万古霉素和替考拉宁治疗重症监护病房耐甲氧西林金黄色葡萄球菌(MRSA)感染的疗效和安全性。方法将36例MRSA感染病人随机分为万古霉素治疗组和替考拉宁治疗组,比较两组病人应用抗生素后的疗效、细菌清除率和不良反应。结果万古霉素与替考拉宁治疗MRSA的治愈率分别为52.6%和58.8%,临床总有效率分别为84.2%和82.3%,细菌清除率分别为84.2%和88.2%,不良反应总发生率为10.5%和0,两组间MRSA治愈率、细菌清除率和不良反应总发生率比较,差异无显著性(P>0.05)。结论替考拉宁和万古霉素对重症监护病房MRSA感染都有很好的治疗作用,临床疗效相似。Objective To compare the effectiveness and safety of vancomycin and teicoplanin in the treatment of methicillin-resistant Staphylococcus aureus （MRSA） infection in intensive care unit （ICU）. Methods Thirty-six patients with MRSA infection were randomly divided into vancomycin group and teicoplanin group. The effectiveness, bacteria clearance rate and side effects in both vancomycin and teicoplanin were compared. Results The cure rates of vancomycin and teicoplanin for MRSA infection were 52.60/00 and 58. 8%, respectively. The total clinical effective rates of vancomycin and teicoplanin were 84. 2% and 88.2%; the bacteria clearance rates were 84.2% and 82.3% l and the incidence of side effects were 10. 5% and 0, respectively. There were no significant differences between the two groups in terms of the above items observed （P〉0.05）. Conclusion Both vancomycin and teicoplanin, with similar effectiveness, show desirable therapeutic effect in the treatment of MRSA infection in ICU.

关 键 词：万古霉素 替考拉宁 重症监护病房 葡萄球菌感染 甲氧西林抗药性 治疗结果 

分 类 号：R378.11[医药卫生—病原生物学]